| human | Q5 |
| P227 | GND ID | 109972554 |
| P213 | ISNI | 0000000005969057 |
| P496 | ORCID iD | 0000-0002-2429-4512 |
| P214 | VIAF ID | 62134139 |
| P10832 | WorldCat Entities ID | E39PBJp64rtX474VHqXgCXFYfq |
| P734 | family name | Schneeweiss | Q37488683 |
| Schneeweiss | Q37488683 | ||
| Schneeweiss | Q37488683 | ||
| P735 | given name | Andreas | Q4926263 |
| Andreas | Q4926263 | ||
| P106 | occupation | oncologist | Q16062369 |
| P21 | sex or gender | male | Q6581097 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q30317570 | 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). |
| Q30315970 | 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts |
| Q59528245 | 15. Internationale St.-Gallen-Konsensus-Konferenz: Behandlung des frühen Mammakarzinoms |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q35110167 | A complex nursing intervention of complementary and alternative medicine (CAM) to increase quality of life in patients with breast and gynecologic cancer undergoing chemotherapy: study protocol for a partially randomized patient preference trial |
| Q45251774 | A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer |
| Q35909540 | ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011. |
| Q33870472 | Acceptance of oral chemotherapy in breast cancer patients - a survey study |
| Q37021210 | Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial |
| Q47552377 | Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study |
| Q54068311 | Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. |
| Q33311401 | Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol |
| Q64231027 | An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study |
| Q38667762 | Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q39388382 | Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial |
| Q37057992 | Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q57808778 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
| Q59595069 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
| Q42440577 | Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour |
| Q35054455 | Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network |
| Q37763649 | Breast cancer and diabetes mellitus |
| Q45995803 | Breast cancer mastectomy trends between 2006 and 2010: association with magnetic resonance imaging, immediate breast reconstruction, and hospital volume. |
| Q35832980 | Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study |
| Q53675136 | Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. |
| Q52849107 | CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. |
| Q39465495 | CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer |
| Q54240384 | Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? |
| Q51340278 | Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? |
| Q59795896 | Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? |
| Q34096326 | Carcinoma of Unknown Primary – an Orphan Disease? |
| Q40202331 | Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study |
| Q40043175 | Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence |
| Q26745444 | Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy |
| Q44594523 | Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression |
| Q35815486 | Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? |
| Q99710705 | Chromothripsis in human breast cancer |
| Q47150180 | Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? |
| Q48230033 | Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer |
| Q34297783 | Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer |
| Q40965602 | Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis |
| Q54294896 | Circulating microRNAs in plasma as early detection markers for breast cancer. |
| Q33958981 | Circulating tumor cells predict survival in early average-to-high risk breast cancer patients |
| Q47260496 | Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years |
| Q45746480 | Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity |
| Q34483478 | Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients |
| Q34284297 | Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer - a Retrospective Analysis |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q47586016 | Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients |
| Q36279137 | Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer |
| Q46927921 | Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences |
| Q31107007 | Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q43100791 | Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system |
| Q46171404 | Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model |
| Q57191514 | DNA methylation array analyses identified breast cancer-associatedHYAL2methylation in peripheral blood |
| Q37665624 | DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. |
| Q36069885 | Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial |
| Q44234056 | Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients |
| Q64982162 | Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. |
| Q64980662 | Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. |
| Q54240388 | Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. |
| Q46703499 | Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial |
| Q41368236 | Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). |
| Q31141769 | Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial |
| Q51888666 | Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. |
| Q52840848 | Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). |
| Q33411565 | Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer |
| Q40395847 | Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer |
| Q38636290 | Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. |
| Q52681182 | Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. |
| Q39843631 | Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma |
| Q34485373 | Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study |
| Q55007492 | Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q43165954 | FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer |
| Q40417378 | Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q39920487 | First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study |
| Q33391647 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q42171728 | Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study |
| Q51943531 | Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. |
| Q51778738 | Generalized lichen ruber planus--induced by radiotherapy of the breast? |
| Q41040904 | Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q53291654 | Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q30313214 | German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients |
| Q30317734 | German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer |
| Q38373098 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial |
| Q28237833 | HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer |
| Q51751068 | HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. |
| Q51891340 | Helical tomotherapy as a new treatment technique for whole abdominal irradiation. |
| Q36237785 | Heterogeneity of miR-10b expression in circulating tumor cells |
| Q38618507 | How the Consolidated Framework for Implementation Research Can Strengthen Findings and Improve Translation of Research Into Practice: A Case Study |
| Q35411077 | Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice |
| Q39162225 | Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q53618240 | Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. |
| Q50866974 | Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. |
| Q39125386 | Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study |
| Q38606464 | Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry |
| Q36198205 | In silico SNP analysis of the breast cancer antigen NY-BR-1. |
| Q38382775 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q44795615 | Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). |
| Q41012013 | Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). |
| Q33574416 | Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study |
| Q33421285 | Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes |
| Q33385484 | Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study |
| Q33384086 | Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer |
| Q58124814 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea |
| Q57270774 | Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis |
| Q37094993 | Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial |
| Q45254004 | Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q49978559 | Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-posit |
| Q45227938 | Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab |
| Q50904556 | Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q48021696 | Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group |
| Q35938054 | Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications |
| Q52589212 | Mechanistic Investigations of Diarrhea Toxicity Induced by anti-HER2/3 Combination Therapy. |
| Q40201374 | Metabolic shifts in residual breast cancer drive tumor recurrence |
| Q39474140 | Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q45174307 | Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene |
| Q36597345 | Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q34654793 | Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences |
| Q38125184 | Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice |
| Q40914660 | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial |
| Q33415041 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial |
| Q30588206 | Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials |
| Q45247406 | Neoadjuvant therapy with gemcitabine in breast cancer |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37108705 | Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial |
| Q46597843 | Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study |
| Q44822009 | Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations |
| Q44838543 | Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy |
| Q52805657 | Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. |
| Q48030360 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials |
| Q30976616 | Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials |
| Q45905465 | Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. |
| Q52874022 | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. |
| Q47124660 | Parity improves anti-tumor immunity in breast cancer patients |
| Q39285061 | Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications |
| Q52867263 | Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. |
| Q39658722 | Personalized therapy in breast cancer |
| Q28291395 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) |
| Q27853134 | Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer |
| Q45928391 | Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. |
| Q53249660 | Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. |
| Q33806358 | Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study |
| Q34022546 | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| Q46094222 | Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer |
| Q38993983 | Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis |
| Q40768670 | Plasma S100P level as a novel prognostic marker of metastatic breast cancer |
| Q41035419 | Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer |
| Q35032320 | Plasma microRNA panel for minimally invasive detection of breast cancer |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q53304516 | Practical experiences with eribulin in patients with metastatic breast cancer. |
| Q35943226 | Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q47999823 | Predictors of Residual Tumor in Breast-Conserving Therapy |
| Q51331347 | Predictors of resectability in breast-conserving therapy. |
| Q35976084 | Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature |
| Q57476250 | Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis |
| Q34621091 | Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. |
| Q38964883 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer |
| Q30316383 | Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). |
| Q50875969 | Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. |
| Q36135274 | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
| Q46829269 | Prognostic factors for patients with liver metastases from breast cancer |
| Q51743804 | Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. |
| Q42677510 | Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q47999353 | Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). |
| Q47126394 | Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer |
| Q36999304 | Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. |
| Q42236299 | Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. |
| Q47894527 | Reply to S. Iwase et al. |
| Q38913971 | Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer |
| Q52882601 | Response-guided neoadjuvant chemotherapy for breast cancer. |
| Q57326030 | Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer |
| Q41641041 | S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer |
| Q30317450 | Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective |
| Q34485182 | Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients |
| Q35608695 | Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study |
| Q48167686 | Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy |
| Q46903050 | Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). |
| Q33425044 | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
| Q26777736 | Targeted Therapies in Triple-Negative Breast Cancer |
| Q34096056 | Targeted Therapy in Breast Cancer. |
| Q38794640 | Targeted Therapy of HER2-Negative Breast Cancer |
| Q57796985 | Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives |
| Q39238692 | Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance |
| Q43800269 | Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel |
| Q46607547 | Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial |
| Q36615770 | The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q33769034 | The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial |
| Q34052424 | The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer |
| Q40234422 | The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies |
| Q47582689 | The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer |
| Q35619770 | The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients |
| Q28389045 | The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial |
| Q53127630 | The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q36321878 | The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features |
| Q41382683 | Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program |
| Q61814603 | Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry |
| Q39996262 | Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers |
| Q33432594 | Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial |
| Q62022868 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer |
| Q47663023 | Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry |
| Q46255000 | Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study |
| Q41612814 | Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry |
| Q61038639 | Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy |
| Q47322152 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy |
| Q47110841 | Update Breast Cancer 2017 - Implementation of Novel Therapies |
| Q52632717 | Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. |
| Q52632715 | Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. |
| Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
| Q59335362 | Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer |
| Q64102998 | Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer |
| Q64102991 | Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice |
| Q64273108 | Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel |
| Q38884752 | Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network |
| Q35771769 | Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories |
| Q56968394 | Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians |
| Q41029345 | Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy |
| Q40187883 | Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study |
| Q48096559 | Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients |
| Q52850868 | Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). |
| Q34096155 | Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer). |
| Q31153453 | pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
| Q61970377 | Änderungen der Stadiengruppierung und Überlebensraten bei Anwendung der neuen TNM-Klassifikation für das Mammakarzinom |
Search more.